This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John J. Voorhees, MD

Arch Dermatol. 1970;101(4):380.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In the 19 years since Gubner first treated psoriasis with methotrexate, its use has gradually become standard practice in the United States and throughout the world. Its effectiveness and the manifestations of acute intoxication are well established, but the safety of prolonged administration remains unknown. That protracted usage may be detrimental has been suggested by several reports from the United States and Europe which indicate chromosomal and hepatic damage in methotrexate-treated psoriatic patients. A report from Utah¹ implicates methotrexate in pulmonary disease as well. The cytogenetic aspect has been recently investigated.² Metaphase chromosomes were analyzed in a total of 6,200 leukocytes from ten healthy adults, nine drug-free psoriatics, and nine psoriatics who had received methotrexate over a long period. No biologically or statistically significant increase in chromosomal abnormalities could be detected in any of these patients. In addition, four of the nine patients who had received previous methotrexate . . . [Full Text PDF of this Article]

Author Affiliations
Department of Dermatology University of Michigan Medical Center Ann Arbor, Mich 48104

Footnotes
This editorial appeared in JAMA under the title "Methotrexate and Psoriasis" (209:1898, 1969).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?